Osimertinib has been approved for treating NSCLC patients with epidermal growth factor receptor (EGFR) T790M mutation after progression on first- or second-generation EGFR-TKIs such as gefitinib, erlotinib and afatinib (4). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.